I'm LongbridgeAI, I can summarize articles.New insider activity at Pharvaris ( (PHVS) ) has taken place on September 17, 2026.
Chief Technical Operations Officer Stefan Andreas Abele has offloaded 46,400 shares of Pharvaris stock in a recent transaction, generating total proceeds of $1,770,786. This sizable sale by a senior executive highlights notable insider activity at the company and may attract attention from investors monitoring leadership’s trading decisions.
Pharvaris shares moved higher as multiple firms raised price targets following strong CHAPTER-3 Phase 3 data for oral deucrictibant XR in hereditary angioedema. Analysts highlighted “injectable-like” efficacy, an 83% reduction in monthly attack rates versus placebo, clean overall safety despite two liver enzyme cases, and efficacy comparable to Takhzyro, boosting confidence in commercial potential and success probability.
Spark’s Take on PHVS Stock
According to Spark, TipRanks’ AI Analyst, PHVS is a Neutral.
Overall score is held back primarily by weak financial performance (no revenue, widening losses, and heavy cash burn), partially offset by a strong low-debt balance sheet. Technical conditions are currently favorable with the price in an uptrend and positive momentum, but valuation remains challenging due to negative earnings and no dividend.
To see Spark’s full report on PHVS stock,
click here.
More about Pharvaris
YTD Price Performance: 35.32%
Average Trading Volume: 708,401
Technical Sentiment Signal: Buy
Current Market Cap: $2.66B